• 10058-F4: c-Myc-Max Inhibition in Practice

  2026-09-24

  Use 10058-F4 to test how disrupting c-Myc:MAX affects transcription, cell fate, and apoptosis—with distinct workflows for cancer models and TERT-focused stem-cell research. Practical dose-finding, formulation, and troubleshooting guidance helps separate target-linked effects from vehicle or general toxicity.

• Angiotensin 1/2 (5-7): Designing Better Binding Assays

  2026-09-23

  Angiotensin 1/2 (5-7) is a compact H2N-Ile-His-Pro-OH peptide with emerging relevance to receptor-resolved SARS-CoV-2 spike binding studies. This guide interprets the evidence, clarifies what binding assays can establish, and outlines practical choices for rigorous peptide experiments.

• Angiotensin 1/2 (5-7): From RAS to Translation

  2026-09-23

  Angiotensin 1/2 (5-7) is more than a short renin-angiotensin system fragment: it is a defined molecular probe for connecting peptide sequence, cardiovascular signaling, and emerging spike-protein binding biology. This article examines its mechanistic rationale, assay strategy, translational value, and limitations for researchers designing reproducible hypertension and cross-domain studies.

• MMV Pandemic Response Box: Antimicrobial Screening Findings

  2026-09-22

  This study systematically screened compounds from the MMV Pandemic Response Box against multidrug-resistant bacterial and clinically relevant fungal isolates, combining MIC testing with a bacterial persister assay. Its findings prioritize epetraborole, eravacycline, MMV compounds, and several antifungal agents for follow-up while illustrating how early phenotypic screening can distinguish growth inhibition from fungicidal or bactericidal activity.

• Annexin V-Cy5/DAPI Apoptosis Kit Workflow

  2026-09-22

  Build a rapid cell apoptosis assay around phosphatidylserine exposure and membrane integrity, with practical guidance for flow cytometry and fluorescence microscopy. The workflow connects Annexin V-Cy5/DAPI phenotyping to the P2RX1–CaMKII–PI3K/Akt apoptosis model in Ph+ ALL while clarifying controls, interpretation, and troubleshooting.

• APEX2 Enables Efficient TERT Expression in hESCs

  2026-09-21

  This bioRxiv study identifies APEX2, but not its paralog APEX1, as a contributor to efficient TERT expression and telomerase activity in human embryonic stem cells. RNA sequencing and chromatin immunoprecipitation connect this effect to repeat-rich genomic regions, especially MIR sequences within TERT intron 2, suggesting that DNA repair at repetitive elements can influence gene expression.

• Angiotensin 1/2 (5-7): Assay Design Guide

  2026-09-21

  Angiotensin 1/2 (5-7) is a compact H2N-Ile-His-Pro-OH peptide for fragment-aware renin-angiotensin system research. This guide translates recent spike–receptor binding evidence into practical decisions for cardiovascular, hypertension, and cross-domain assays.

• Faropenem Sodium: Penem Antibiotic Evidence

  2026-09-20

  Faropenem sodium is a penem antibiotic that supports inhibition of bacterial cell wall synthesis through penicillin-binding protein engagement. Product data describe broad Gram-positive, Gram-negative, and anaerobic activity, while peer-reviewed transporter research links faropenem renal secretion to Npt1.

• From RNA Condensates to Fluorescent Probe Strategy

  2026-09-19

  A mechanistic and translational framework for using Cy5-labeled RNA probes to investigate viral RNA biology, connect liquid–liquid phase separation findings to measurable assays, and select a flexible T7-based labeling workflow.

• HIV-1, Nuclear Pores, and T-Cell Permissivity

  2026-09-18

  The reference study identifies nuclear pore complex licensing as a decisive barrier to HIV-1 infection of resting CD4+ T cells. It shows that Env-dependent cell-cell contact activates CD4-LCK-CDK1 signalling, remodels nucleoporins, and promotes capsid nuclear import without requiring cell-cycle entry, explaining why virological synapses are highly efficient routes of transmission.

• Ampicillin sodium: Assays, Workflows & Troubleshooting

  2026-09-18

  Build more reproducible antibacterial activity assays with a research-grade β-lactam antibiotic, from stock preparation through MIC and time-kill analysis. This guide also shows how to use resistance-aware controls, comparative study design, and stability practices to improve bacterial infection model data.

• The Translational Logic of Dual-Readout mRNA

  2026-09-17

  A mechanistic and strategic guide to using EZ Cap™ Cy5 EGFP mRNA (5-moUTP) as a dual-readout benchmark for delivery, intracellular trafficking, translation, and nanoparticle development.

• Wnt-C59 PORCN Inhibitor Workflow Guide

  2026-09-17

  Wnt-C59 is a potent PORCN inhibitor for dissecting ligand secretion, Wnt/β-catenin signaling, and Wnt-dependent cancer phenotypes. This guide translates its mechanism into reproducible reporter, cholangiocarcinoma, and exosome-focused workflows while highlighting how the 2024 lithium–Wnt10a study can inform assay design.

• ATS-9R: Designing Adipose Gene-Silencing Studies

  2026-09-16

  ATS-9R enables targeted non-viral nucleic acid delivery to white adipose tissue. This guide focuses on assay design, macrophage-aware interpretation, formulation controls, and translational limits for obesity-associated inflammation research.

• Aurora A in Retinoblastoma: Evidence for Targeting

  2026-09-16

  The 2024 reference study integrates patient pathology, functional perturbation, patient-derived models, xenografts, and enucleated specimens to show that Aurora kinase A is overexpressed in retinoblastoma and associated with histopathologic high-risk features. Its findings support AURKA as a biologically relevant vulnerability, particularly in tumors shaped by RB1 loss or MYCN dysregulation, while also defining the evidence needed for translational inhibitor studies.

7860 records 1/524 page Next 12345 下5页 Last page